Valerio Therapeutics is a clinical-stage biotechnology company that develops innovative DNA decoy therapeutics for oncology and inflammatory diseases. Self-described as leading in the development of first-in-class treatments.

Valerio Therapeutics

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Valerio Therapeutics Société anonyme

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 27, 2024 6:07 PM	9da5d86c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 6:07 PM	0edf1784
crunchbase trigger	general	Nov 27, 2024 12:50 PM	205f8008
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 27, 2024 6:07 PM	e9436aff
news basic	general	Sep 27, 2024 6:07 PM	339ea0fe
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VALERIOTX

Valerio Therapeutics

Last Close

0.08

25/11 08:24

Market Cap

15.49M

Beta: -

Volume Today

7.30K

Avg: -